Modified oral enteric-coated budesonide regimens to treat pediatric eosinophilic gastroenteritis, a single center experience
Authors:
- 1 July 2019
- journal article
- letter
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 7 (6) , 2059-2061
Abstract
No abstract availableFunding Information
- DBV Technologies
- Aimmune Therapeutics
- Danone
- National Institutes of Health
- Food Allergy Research and Education
- Medscape
- Uptodate
This publication has 9 references indexed in Scilit:
- Eosinophilic gastrointestinal diseases beyond eosinophilic esophagitisAnnals of Allergy, Asthma & Immunology, 2018
- Prevalence of Eosinophilic Gastritis, Gastroenteritis, and ColitisJournal of Pediatric Gastroenterology and Nutrition, 2016
- Efficacy of Dietary Treatment for Inducing Disease Remission in Eosinophilic GastroenteritisJournal of Pediatric Gastroenterology and Nutrition, 2015
- Eosinphilic Gastroenteritis: A Case Series Highlighting Manifestations and Response to Therapy in 20 Pediatric PatientsJournal of Allergy and Clinical Immunology, 2015
- “Triple Phase” Budesonide Capsules for the Treatment of Olmesartan-Induced EnteropathyAnnals of Pharmacotherapy, 2014
- Variation in Prevalence, Diagnostic Criteria, and Initial Management Options for Eosinophilic Gastrointestinal Diseases in the United StatesJournal of Pediatric Gastroenterology and Nutrition, 2011
- Localized eosinophilic ileitis with mastocytosis successfully treated with oral budesonideAllergy, 2007
- Eosinophilic gastroenteritis with severe protein-losing enteropathy: Successful treatment with budesonideDigestive and Liver Disease, 2006
- Eosinophilic gastroenteritis treated with non-enteric-coated budesonide tabletsEuropean Journal of Gastroenterology & Hepatology, 2001